CLAIMS

1. Use of composition in the manufacture of a medicament for immunizing a subject in need thereof against an influenza virus, the composition comprising:

(a) a recombinant hemagglutinin (rHA) from an influenza virus, and

(b) an adjuvant, wherein the adjuvant comprises a disaccharide having a reducing and a non-reducing terminus each independently selected from glucosyl and amino substituted glucosyl, where a carbon at a 1 position of the non-reducing terminus is linked through either an ether (-O-) or amino (-NH-) group to a carbon at a 6' position of the reducing terminus, the disaccharide being bonded to a phosphate group through a 4' carbon of the non-reducing terminus and to a plurality of lipid groups through amide (-NH-C(O)-) and/or ester (-O-C(O)-) linkages, where the carbonyl (-C(O)-) group of the ester or amide linkage is directly linked to the lipid group, and each lipid group comprises at least 8 carbons, ~~and~~

wherein the composition is dosage sparing, wherein the composition is to be administered by way of a single injection and wherein the amount of rHA per dose is in the range of 15 to 0.1μg.

2. Use of a composition in the manufacture of a medicament for immunizing a subject in need thereof against an influenza virus by way of a single injection of the medicament, the composition comprising:

(a) a recombinant hemagglutinin (rHA) from an influenza virus and

(b) an adjuvant, wherein the adjuvant comprises a disaccharide having a reducing and a non-reducing terminus each independently selected from glucosyl and amino substituted glucosyl, where a carbon at a 1 position of the non-reducing terminus is linked through either an ether (-O-) or amino (-NH-) group to a carbon at a 6' position of the reducing terminus, the disaccharide being bonded to a phosphate group through a 4' carbon of the non-reducing terminus and to a plurality of lipid groups through amide (-NH-C(O)-) and/or ester (-O-C(O)-) linkages, where the carbonyl (-C(O)-) group of the ester or amide linkage is directly linked to the lipid group, and each lipid group comprises at least 8 carbons and wherein the amount of rHA per dose is in the range of 15 to 0.1μg.

~~3. The use of any one of claims 1-2, wherein the amount of rHA per dose is in the range of about 15 to about 0.1μg.~~

~~4.~~3. The use of claims 1 or 2~~-3~~ wherein the amount of rHA per dose is in the range of ~~about~~ 10 to ~~about~~ 0.5μg.

~~5.~~4. The use of claim ~~4~~ 3 wherein the amount of rHA per dose is in the range of ~~about~~ 5 to ~~about~~ 1μg.

~~6.~~5. The use of any of claims 1 or 2~~ or 3~~, wherein the adjuvant is glycopyranoside Lipid A (GLA) and the rH5 is from a pre-pandemic or pandemic influenza virus.

~~7.~~6. The use of claim ~~6~~5, wherein the influenza virus is selected from the group consisting of: H5N1, H1N1, H7N7, H9N2, H3N2, avian flu, H5, and H5 clade 1, H5 clade 2, H5 clade 4, and H5 clade 7 viruses.

~~8.~~7. The use of claim ~~7~~ 6 wherein the influenza virus is H5.

~~9.~~8. The use of claim 1, wherein the rHA is present at a concentration that does not provide protective immunity in the absence of the adjuvant.

~~10.~~9. The use of any of claims ~~3~~ 1 to 9, wherein the composition comprises a single recombinant protein.

~~11.~~10. The use of any of claims ~~3~~ 1 to 9, wherein the composition comprises more than one HA.

~~12.~~11. The use of claim 1 or 2 ~~or 3~~ for immunizing a population against an influenza virus, wherein administration of the composition achieves seroconversion in at least 50% of the population after the single injection.

~~13.~~12. The use according to any one of the preceding claims wherein the composition does not include an emulsion.

~~14.~~13. The use according to any one of the preceding claims wherein the composition does not include oil.

~~15.~~14. The use according to any one of the preceding claims wherein the adjuvant is glycopyranoside Lipid A (GLA).